Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1992-12-04
1999-07-13
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514912, 514913, A61K 31135
Patent
active
059227737
ABSTRACT:
Elevated glutamate levels are associated with glaucoma, and damage to retinal ganglion cells can be controlled by administering to the patient a compound capable of reducing glutamate induced excitotoxicity in a concentration effective to cause reduction of such excitotoxicity.
REFERENCES:
patent: 4158005 (1979-06-01), Bodor et al.
patent: 4396625 (1983-08-01), Yamamori et al.
patent: 4425346 (1984-01-01), Horlington
patent: 4981871 (1991-01-01), Abelson
patent: 5017579 (1991-05-01), Gubin et al.
patent: 5070088 (1991-12-01), Atwal et al.
patent: 5435998 (1995-07-01), Abelson
Dreyer et al., Excitatory Aminoacids in Glaucoma: A Potentially Novel Etiology of Neuronal Loss in this Optic Neuropathy, Society for Neuroscience Abstracts 18:439 (1992).
Dreyer et al., A Proposed Role for Excitatory Amino Acids in Glaucoma Viral Loss, Investigative Ophthalmology and Visual Science 34:1504 (1993).
Nathanson, Nitrovasodilators as a New Class of Ocular Hypotensive Agents, Journal of Pharmacology and Experimental Therapeutics 260:961 (1992).
Dreyer, Amino Acid Analysis of Vitreous Specimens in Patients with Open Angle Glaucoma, Ophthalmol. Visual Science 32:871 (1991).
Sommer et al., Tips 13:291-296, 1992.
Sucher et al., The Journal of Neuroscience 11:966-971, 1991.
Sucher et al., Brain Research 297:297-302, 1991.
Nakanishi, Science 258:597-603, 1992.
Meldrum et al., Tips 11:379-387, 1990.
Moriyoshi et al., Nature 354:31-37, 1991.
Finkelstein et al., British J. of Ophthalmology, 74:280-282, 1990.
Watkins et al., Tips 11:25-33, 1990.
Hess, Annu. Rev. Neurosci. 13:337-56, 1990.
Levy et al., Neurology 40:852-855, 1990.
Faden et al., Science 244:798-800, 1989.
Karschin et al., J. of Physiology 418:379-396, 1989.
Bean, Annu. Rev. Physiol. 51:367-84, 1989.
Hahn et al., Proc. Natl. Sci. USA 85:6556-6560, 1988.
Lipton et al., J. Physiol. 385:361-391, 1987.
Svenneby et al., Biochemical Society Transactions 15:213-215, 1987.
Rosenthal, Amer. J. Ophthalmology 102:570-574, 1986.
Sisk et al., Graefe's Archive Clin. Exp. Ophthalmol. 223:250-258, 1985.
Hannappel et al., Ophthalmic Res. 17:341-343, 1985.
Ehlers, Acta Ophthalmologic 59:576-586, 1981.
Quigley et al., Arch Ophthalmol 99:635-649, 1981.
Quigley et al., Invest. Ophthalmol. Vis. Sci. 19:505-517, 1980.
Schonheyder et al., Acta Ophthalmologica 53:627-634, 1975.
Hayreh, Brit. J. Ophthal. 58:863-876, 1974.
Ehlers et al., Acta Ophthalmologica, Jun. 1973.
Durham et al., Clinical Chemistry 17:285-289, 1971.
Durham, Tr. Am. Ophth. Soc., 68:462-500, 1970.
Olney, J. Neuropathology and Exp. Neurology, IIVIII:455-474, 1969.
Dickinson et al., Investigative Ophthalmology, 7:551-563, 1968.
Lucas et al., A.M. A. Archives of Ophthalmology, 58:193-201, 1957.
Dreyer Evan B.
Lipton Stuart A.
Fay Zohreh
Massachusetts Eye and Ear Infirmary
The Children's Medical Center Corp.
LandOfFree
Glaucoma treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glaucoma treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glaucoma treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2276124